Manufacturing again targeted in Arena cost cutting

Boxes

Arena, developer of obesity med Belviq, knows something about slimming down. For the second time in 9 months, the San Diego-based drug company will slim itself, cutting jobs and costs, with manufacturing again taking a hit.

Arena ($ARNA) said last week it is cutting its workforce by 73% as it pivots its focus to its clinical-stage pipeline and as Belviq sales fail to develop as it had hoped. It will eliminate about 100 jobs in the process. The job cuts will hit manufacturing, as well as research and general and administrative functions. The company expects it will cut annual costs by between $23 million and $25 million. It was short on details but said that it “plans to implement additional cost control measures to further reduce its expenditures, including reductions at its Swiss manufacturing facility.”

The reorganization is no surprise given the difficulties that Belviq has faced since launching in 2013. Despite a hefty investment from marketing partner Eisai--a DTC campaign and a rep army hundreds strong--the med has not taken off. In last year’s Q4, Arena netted just $3.9 million in royalties on just $8 million in Eisai sales--a topline haul for the Japanese drugmaker that declined for the fourth straight quarter.

Survey

Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

In October, Arena had made similar cuts. At that time, it said it would reduce its U.S. workforce by 35%, about 80 employees, in an effort to realize about $11 million in annual costs. In October, it also indicated it would do "additional cost-cutting, including at its Swiss manufacturing facility."

- here’s the release

Related Articles: 
Arena chops 100-plus jobs as it shifts its priorities from struggling Belviq 
Elsai slashes Belviq sales force as Arena marketing deal goes sour 
Investors cheer as Arena forces out CEO and cofounder

Read more on

Suggested Articles

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.